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Abstract
Squamous cell carcinoma (SCC) of the lung is a frequent and aggressive cancer type. Gene amplifications, a known
activating mechanism of oncogenes, target the 3q26-qter region as one of the most frequently gained/amplified genomic
sites in SCC of various types. Here, we used array comparative genomic hybridization to delineate the consensus region of
3q26.3 amplifications in lung SCC. Recurrent amplifications occur in 20% of lung SCC (136 tumors in total) and map to a core
region of 2 Mb (Megabases) that encompasses SOX2, a transcription factor gene. Intense SOX2 immunostaining is frequent
in nuclei of lung SCC, indicating potential active transcriptional regulation by SOX2. Analyses of the transcriptome of lung
SCC, SOX2-overexpressing lung epithelial cells and embryonic stem cells (ESCs) reveal that SOX2 contributes to activate ESC-
like phenotypes and provide clues pertaining to the deregulated genes involved in the malignant phenotype. In cell culture
experiments, overexpression of SOX2 stimulates cellular migration and anchorage-independent growth while SOX2
knockdown impairs cell growth. Finally, SOX2 over-expression in non-tumorigenic human lung bronchial epithelial cells is
tumorigenic in immunocompromised mice. These results indicate that the SOX2 transcription factor, a major regulator of
stem cell function, is also an oncogene and a driver gene for the recurrent 3q26.33 amplifications in lung SCC.
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Introduction
Recurrent chromosomal aberrations represent driving forces of
tumor progression and historically have led to the identification of
tumor suppressor genes and oncogenes critical for several cancer
types [1]. Gene copy number increases, such as gene amplifica-
tions, are well-known oncogene activating mechanisms, affecting
their expression by gene dosage [2,3]. Amplification of canonical
oncogenes, such as EGFR, ERBB2, C-MYC, N-MYC, CCND1,
MDM2 and RAS, have been found in 10 to 30% of cases of the
different cancers types in which they play a central role [2]. In
squamous cell carcinomas (SCCs), chromosome 3 aberrations are
among the most prevalent. Recurrent deletions on the 3p arm and
gains on the 3q arm are present in the majority of cases, whereas
gene amplifications cluster in the 3q26–q29 region [4,5]. Several
amplicon units at 3q26-qter have been postulated to be implicated
in the disease [6,7]. At 3q26.3, the DCUN1D1 gene has been
recently proposed as an oncogene in lung SCC [8]. Nevertheless,
the precise location and frequency of 3q26.3 amplifications in lung
SCC remain unclear. In addition, more than one oncogene can be
co-activated within an amplicon and synergistically participate in
different tumor traits, as exemplified for another locus in lung
adenocarcinoma [9]. Therefore, precise mapping of the amplifi-
cation region and firm demonstration of oncogenic properties of
individual genes from the amplicon will permit assessment of their
relative contribution to the tumor phenotype.
To delineate regions of chromosome 3 alterations with precision,
we screened genomic unbalances in 26 lung SCCs using high-
resolution dedicated arrays. We selected operable locally advanced
(stage III) lung SCC because advanced tumors have a tendency to
contain more genomic aberrations, including gene amplifications,
selected during tumor progression [10]. We uncovered a core
amplified region of 2 Mb at 3q26.33 containing nine genes, which
include DCUN1D1 and the transcription factor SOX2.
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8960SOX2 (abbreviation of sex-determining region Y-box 2) is a 317
aminoacid transcription factor containing an HMG domain and a
critical transcription regulator of normal stem cell function in
embryonic and neural stem cells [11–13]. SOX2 is a major
stemness factor. Indeed, it is a critical transcription regulator of the
normal stem cell phenotype of ESCs, with a restricted number of
partners, including Oct-4 and Nanog. It controls self-renewal and
differentiation processes through coordinated transcriptional
programs [11,12]. Likewise, SOX2 is a major regulator of stem
cell function in NSCs (Neural Stem Cells) [13]. SOX2 is one of the
‘‘magical four’’ crucial transcription factors capable of cooperating
to reprogram differentiated cells into an induced pluripotent stem
cell-like phenotype [14,15].
In murine lung development, SOX2 controls branching
morphogenesis and epithelial cell differentiation, and its over-
expression leads to an increase in committed precursor-like cells,
notably basal cells [16]. In all of these individual situations, SOX2
modulates coordinated transcriptional programs that are depen-
dent on available cofactors in the cellular context.
Here, we show that SOX2 has a major impact on global lung
SCC transcriptome deregulation and contributes to activate ESC-
like transcriptome phenotypes, thereby establishing SOX2 as a key
up-regulated transcription factor in lung SCC which modulates
both direct and indirect key target genes involved in tumor
progression. Over-expression in human lung epithelial cell grafts
in immunocompromised mice led to the formation of poorly
differentiated squamous tumors with basaloid traits. Together, our
work identifies SOX2 as an oncogene and likely driver gene of one
of the most frequent amplification sites in lung SCC.
Results
Array Comparative Genomic Hybridization Screening for
Chromosome 3 Aberrations in Lung SCC
To delineate chromosome 3 consensus regions of deletions and
gains/amplifications, we analyzed 26 advanced stage lung SCCs
using a chromosome 3-dedicated array composed of 214 genomic
clones. All data are available in GEO (GSE15080). Losses on the
3p arm, gains of large 3q regions and high-level amplifications at
3q26-qter were found (Figure 1 panel A–B). Deletions mostly
occurred on the 3p arm and seemed to affect several sites. Among
genomic positions evaluated on the short arm, the interval from 8
to 10 Mb, (containing OGG1 and RAD18) was the most frequently
lost (60% of tumors). Large gains often targeted the 3q arm, with a
global gain of the 3q26-qter (176–196 Mb) region in 60% of
tumors. Two interval regions, from 180 to 182 Mb (including the
PIK3CA locus) and from 188 to 190 Mb (including the RFC4/SST
locus) were gained in about 80% of tumors. Frequent high-level
amplifications clustered in the 3q26-qter region (Figure 1 panel B),
with a maximum for clone RPCI11-259I19 amplified in nearly
20% (5/26). This clone is located at 3q26.33, between SOX2 and
DCUN1D1 (Figure 1 panel F). Whole genome surveys of the two
tumors with the most accentuated amplifications revealed that the
highest copy number levels across all chromosomes were located at
3q26.33 (Figure S1, panel A).
To estimate the general relevance of these findings, we explored
pangenomic array-CGH data in additional and independent
cohorts of SCCs from the lung or uterine cervix. We found
consistent results with the most common amplification at the same
locus in a second independent cohort of 76 lung SCCs (N.
Martinet and S. du Manoir, unpublished data). In addition, in a
third independent cohort (34 lung SCCs, GSE12280, [17]), two
genomic regions are amplified recurrently (.20% of the tumors),
including the 3q26.33 locus represented by the clone RP11-
701O19 (Figure 1 panel C–D). This clone maps between the FXR1
and SOX2 genes (Figure 1panel F ). Furthermore, in uterine cervix
SCCs (GSE6473, [18]; GSE11573, [19]), this locus is the most
frequently amplified on chromosome 3 (4 to 10% of cases, Figure
S1 panel B). In conclusion, the 3q26.33 locus undergoes copy
number increase in a high percentage of lung SCCs (60 to 80%),
and high-level amplifications recurrently occur in 20% of the
tumors in three independent cohorts (.130 lung SCCs in total).
Finally, this site is one of the most commonly affected in uterine
cervix SCC, showing that 3q26.33 is a recurrently altered locus in
SCCs and likely involved in their pathogenesis.
High-Resolution Mapping of Recurrent 3q26.33
Amplicons in Lung SCC
To refine mapping of the 3q26.33 amplifications, we built a
3q26.3–3q27 tiling array (from 177 Mb to 186 Mb). Re-analysis of
the five tumors with amplifications confirmed the presence of
3q26.33 amplicons in each case and allowed us to delineate their
size exemplified for two cases (Figure S1 panel C–D). The core
amplicon in these tumors was a segment of slightly less than 2 Mb
in size, mainly covering the 3q26.33 band and a small segment of
3q27.1 (Figure 1 panel E–F). We listed the gene content in a
slightly larger region of 2.7 Mb (from 181.9 to 184.6 Mb) to take
into account the high-level gains of neighboring regions. Nine
known genes were included in this genomic interval and stand as
oncogene candidates to be activated by recurrent 3q26.33
amplifications (Figure 1 panel F).
Candidate Genes Expression Levels and 3q26.33 Copy
Number Changes in Lung SCC
To determine the extent to which the nine candidate genes at
3q26.33 were differentially expressed in lung SCC, we analyzed
published, genome-wide transcriptome datasets [20,21] through
Oncomine [22] (Figure 2 panel A–B). LAMP3 expression is greatly
down-regulated, whereas FXR1, ATP11B, DCUN1D1 and SOX2
are significantly up-regulated in primary tumors compared to
normal lung. Importantly, SOX2 is over-expressed in about 90% of
the tumors and is among the top 50 genes (rank 21) most strongly
over-expressed in lung SCC, together with several classical
squamous markers, such as keratins and p63 (Figure 2 panel C
and Table S1). To discriminate between driver and by-stander
genes within the 3q26.3 core amplicon, we next investigated the
expression levels of the nine candidate genes in the five tumors
with 3q26.3 genomic amplifications, in comparison to tumors with
low level gains or with normal copy number, using RT-qPCR. In
the five tumors with amplifications, all of the genes, with the
exception of LAMP3, were recurrently over-expressed (four out of
five tumors with an expression ratio .2) except LAMP3 (Figure 2
panel D and E). However, recurrent strong over-expression (four
out of five tumors with a ratio .5) is found only for SOX2 and
SOX2OT. In the two tumors with low-level gains (Figure 2 panel
F), the two highly up-regulated genes were also SOX2 and
SOX2OT. In conclusion, eight out of the nine tested genes were
recurrently over-expressed, but SOX2 and SOX2OT were the most
consistently highly over-expressed and thus are the best candidates
to be driver genes of 3q26.3 amplifications.
Immunohistochemical Analysis of SOX2 in 51 Human
Lung SCCs
We investigated SOX2 protein expression by immunohisto-
chemistry in 51 lung SCCs (these cases included the 26 advanced
stage lung SCCs studied by array-CGH). Staining was scored
according to intracellular localization, intensity and the percentage
SOX2 Is an Oncogene in LSCC
PLoS ONE | www.plosone.org 2 January 2010 | Volume 5 | Issue 1 | e8960Figure 1. Characterization of chromosome 3 aberrations in lung SCC using array-CGH. A. Frequency of chromosome 3 losses and gains in
26 advanced lung SCCs. For each 2 Mb interval along chromosome 3, frequencies were calculated by dividing the total number of occurrences of
losses or gains observed in the series by the total number of possible occurrences, expressed as percentages and represented along the
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presented in Table S2. In the normal human lung, SOX2 staining
was mainly observed in bronchial epithelial cells (but not alveolar
cells, Figure 3 panel A), where nuclear SOX2 expression was
restricted to a sub-population (30%) of bronchial epithelial cells. In
tumors, a few cases incidentally harbor strong and exclusively
cytoplasmic staining (five cases, 10%), and the five cases with
3q26.33 amplifications display strong nuclear staining in nearly all
tumor cells (.80%) with the highest signal scores (Figure 3 panel
B). Overall, 34/51 tumors (67%) have an increased nuclear Sox2
staining score (Figure 3 panel C). In conclusion, the Sox2
transcription factor is strongly expressed and localized in the
nucleus in the wide majority of lung SCCs, showing that Sox2 is
recurrently activated and suggesting that it may consequently
regulate a coordinated and specific transcriptional program in
lung SCC.
We thus wondered whether Sox2-dependent expression signa-
tures could be detected in these tumors. We analyzed two
independent human lung SCC genome-wide transcriptome
datasets (dataset-1 [20]; dataset-2 [21]) and defined lung SCC
signatures (genes that were differentially expressed in lung SCC vs.
normal comparison, see Genelist S1). Our objectives were: first, to
comprehensively characterize lung SCC molecular phenotypes at
the transcriptome level; and second, to assess the contribution of
SOX2. Previous studies have clearly established that molecular
signature comparisons are more robust when carried out at an
integrative level to reveal their relative enrichments [23,24], using
a knowledge-based and/or concomitantly expressed group of
genes, such as gene modules [25]. These powerful approaches
condense independent and multiple experimental observations
into definite modules of genes that are coordinately activated or
repressed in a large compendium of experiments.
Stem Cell-Like Transcriptome Phenotypes in Human
Lung Squamous Cell Carcinoma
Accordingly, we searched for enrichments of the lung SCC
signatures in the Molecular Signatures Database (see Text S1). We
found enrichments of a meta-signature of poorly differentiated
human cancer [26] (Figure 4 panel A). More surprisingly, we also
uncovered highly significant enrichments of ESC and NSC
signatures in the lung SCC signatures. To follow this clue, we
retrieved compiled ESC-like signatures recently issued in two large
scale meta-analyses [27,28]. From a large and curated compen-
dium of stem cell profiling experiments, an ESC-like gene module
was isolated and shown to be activated in several human epithelial
tumor types. Its activation correlates with poor prognosis in breast
and lung adenocarcinoma [28]. Similarly, a meta-analysis [29] has
permitted the compilation of a human ESC consensus gene
module that is activated in poorly differentiated, high grade breast,
glioblastoma and bladder cancers [27]. We addressed the question
of the similarity between the lung SCC transcriptome and these
ESC-like molecular signatures. Both the hESC consensus and the
hESC-like modules were highly significantly enriched in primary
SCC (all FDR ,0.02, 23-34% of the modules; Figure 4 panel B
and Figure S2 panel A, see Genelist S1). Our findings show that
stem cell-like molecular phenotypes are activated in lung SCC,
and the frequent nuclear staining observed in tumors is consistent
with a SOX2 transcriptional regulation function, leading us to
further dissect the impact of SOX2.
SOX2 Contribution to Stem-Cell Like Transcriptome
Phenotypes in Lung SCC
Promoter analyses revealed over-representation of SOX proteins
binding sites in the lung SCC signatures (notshown), consistent with
an imprint of SOX2 activity on these transcriptomes. SOX2 is a
major regulator of stem cell function in both ESCs and NSCs,
controlling SC fate and self renewal. Accordingly, SOX2 targets
have been extensively identified in this cellular context. We
intersected the lists of genes that are differentially expressed [29]
and have SOX2-bound promoters in ESCs [11] to generate a
curated list of 345 known direct SOX2 target genes in human ESCs
(242 and 103 genes that SOX2 activates or represses, respectively,
see Genelist S1). We compared this list of known SOX2 targets to
the lung SCC signatures and found significant overlaps (Figure 4
panel C). In fact, approximately 4% of the genes comprising the
lung SCC signatures are known SOX2 targets in hESCs. This
enrichment was further confirmed by GSEA-based analyses (Gene
Set Enrichment Analysis, Figure 4 panel D and Figure S2 panel B).
For comparison, we performed identical analysis for the c-Myc
oncogene with a curated list of 415 known c-Myc target genes and
uncovered similar proportions(5.2%and 3.2%of deregulatedgenes
in lung signatures -1 and -2, respectively). To conclude, a significant
proportion of direct SOX2 target genes are deregulated in lung
SCC to an extent comparable to a well-established oncogenic
transcription factor. This finding is strongly in favor of a notable
SOX2 impact on the lung SSC transcriptome.
ToaddressthequestionofwhetherSOX2contributestothestem-
cell like molecular traits of lung SCC, we performed transcriptome
chromosomal order. Gaps are due to intervals with no coverage on the array. Frequent 3p losses seem to affect discontinuous zones. The most
frequently lost region is the 8–10 Mb interval (around 60% of samples). Gains were more frequently detected on the 3q arm: 3q26-qter was gained in
50–60% of the samples with two discrete intervals (180–182 and 188–190 Mb, denoted by asterisks) gained in around 80% of tumors. B. High level
chromosome 3 amplification frequency in 26 advanced lung SCCs. For a given clone, a ratio greater than 2 (1 in log2 scale) in a single experiment was
considered to represent a high-level amplification. Frequencies were calculated for the series of 26 cases and plotted according to clone localization.
High level amplifications cluster in the 3q26-qter region. A peak maxima is observed for BAC clone RP11-259I19; high level amplifications of this locus
are found in 20% of cases (5/26 tumors). C. Whole genome high level amplification frequencies in 34 advanced lung SCCs (independent cohort).
Chromosome numbers are indicated above the graph, and different chromosomes are separated by vertical gray lines. For a given clone, a ratio
greater than 1.5 in log2 scale in a single experiment was considered to represent a high-level amplification. Frequencies were calculated for the series
of 34 cases and plotted according to clone localization on the genome. Two genomic regions, on chromosomes 3 and 4 were amplified in .20% of
the cases. D. High level chromosome 3 high level amplification frequency in 34 advanced lung SCCs (independent cohort). The graph corresponds to
panel C restricted to chromosome 3. E. Individual array-CGH profiles obtained for the five tumors with high level 3q26.3 gene amplifications. High
ratio deviations were observed for two tumors with straight amplicon boundaries (#15 and #35). The consensus region of 3q26.3 amplifications is a
2.7 Mb segment spanning the 181.9–184.6 Mb interval (denoted by a grey rectangle). F. UCSC genome browser map of the 3q26.33 consensus
region of amplifications in lung SCCs. This fully sequenced and assembled genomic region (181.9–184.6 Mb, NCBI build 34) contains nine genes
(Refseq), including DCUN1D1 and SOX2, and various Genbank mRNAs. This image was downloaded from the UCSC genome browser (http://genome.
ucsc.edu/, [64,65]). The green arrows in panels B and C/D point to BAC clones RPCI11-259I19 and RPCI11-701O19, respectively, corresponding to the
maxima of chromosome 3 amplification in these lung SCC cohorts. RPCI11-259I19 and RPCI11-701O19 are mapped, respectively, between the SOX2
and DCUN1D1, and FXR1 and SOX2, genes. Two different clones were found due to the composition of the two arrays (RPCI11-259I19 in our Chr3 array
and RPCI11-701O19 in the GSE12280 array). Mapping of the amplification by two independent clones suggest that it is not a clone-derived artifact.
doi:10.1371/journal.pone.0008960.g001
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PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8960Figure 2. Transcriptional consequences of 3q26.33 copy number increases in lung SCC. Panels A and B: expression levels of 3q26.33
genes in lung SCCs versus normal comparisons using microarrays and Oncomine. Each graph represents normalized log2 expression values of a given
gene in normal lung and lung SCC samples. The clone (panel A) or Affymetrix probe set (panel B) number is indicated under the gene name. The log2
value ratio (average expression value in SCC)/(average expression value in normal lung) and the corresponding p-value are indicated. A. Lung SCC
dataset-2. Among the five genes that were analyzable and represented (FXR1, DNAJC19, ATP11B, DCUN1D1, and B3GNT5), FXR1, ATP11B, and DCUN1D1
are significantly over-expressed in lung SCCs (all with p,10
22). B. Lung SCC dataset-1. Four genes localized in the 3q26.3 core amplicon are
represented on the microarray (FXR1, SOX2, ATP11B, and LAMP3). LAMP3 is strongly down-regulated in the tumors (p,10
28). ATP11B (p,10
22) and
SOX2 (p,10
28) are significantly over-expressed in lung SCCs. C. Top 100 genes deregulated in lung SCC dataset-1 using GenePattern. These genes
include SOX2 (red rectangle) among the top 50 genes over-expressed in lung SCCs compared to normal lung. In this dataset, four genes (FXR1, SOX2,
ATP11B, and LAMP3) out of the nine localized in the core amplicon were represented on the array. For each gene in each sample, expression is
represented by a square with a color that codes for the level as a gradient (dark blue, low expression, to dark red, strong expression). D. Expression
levels of nine genes from the consensus region in the tumors with high level 3q26.3 amplifications. The identical y-scale for all graphs represents the
expression ratio for a given gene when compared to its relative average expression level in two lung SCCs without copy number change of the
3q26.3 locus. Genes are ranked from left to right according to 3q26.33 genomic localization, and names are represented below the bottom graph. E.
Summary of over-expressed genes in the five lung SCCs with high-level 3q26.3 amplifications. Two genes, SOX2 and SOX2OT, are consistently over-
expressed in tumors with 3q26.3 copy number increases when compared to tumors with a normal copy number of the locus. Other genes are
recurrently over-expressed but at lower levels when compared to SOX2 and SOX2OT. F. Two tumors with low-level copy number gains of the 3q26.3
locus were analyzed as in panel D. SOX2 and SOX2OT are the most over-expressed genes in these tumors. Panels D and F: Sample numbers are
indicated on the right of the graphs. Insets in tumor #35 and #10 graphs correspond to y-axis extended scale to fold-change values of 200 and 100,
respectively. Fold-changes represent the mean 6 sem of three independent experiments.
doi:10.1371/journal.pone.0008960.g002
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expression profiles that correlate with SOX2 in primary tumors
(GSEA-based correlative analyses). We created a simple in vitro
cellular model of human bronchial epithelial cells by stably over-
expressing SOX2 in the BEAS-2B immortalized and non-tumori-
genic cell line [30]. We found 922 differentially expressed genes
betweenSox2-transduced and controlcellsthatcomprisethe SOX2-
squamous signature (see Genelist S1). As expected, the promoters of
these genes were enriched with SOX protein binding sites (p,10
26).
Additionally, the SOX2-squamous signature in BEAS-2B cells
significantly overlaps with the known direct SOX2 targets defined in
hESCs. Moreover, this signature is enriched in several GO
categories (Figure S3 panel A–C). More interestingly, SOX2 over-
expression in this in vitro model led to activation of a significant
proportion of genes from the human ESC-like gene module (Figure
S3 panel D; FDR =0.12, 292 genes, 23% of the module). Finally, to
further assess the contribution of SOX2 to the activation of ESC-like
modules in primary tumors, we performed correlative analyses using
GSEA. Genes with expression profiles that correlated with SOX2
expression in the lung SCC datsaset-1 (no valid SOX2 probe is
present in dataset-2) were found to be significantly enriched for the
hESC consensus (FDR ,10
22) and hESC-like (FDR ,0.07)
modules (Figure 4 panel E). These results demonstrate that human
lung SCCs have marked ESC-like molecular phenotypes: 23 to 34%
of the genes from ESC-like modules, which were shown to be
activatedinaggressiveepithelialtumors,areconsistentlyexpressedin
human lung SCC. In primary lung SCC, as well as in in vitro over-
expressing cells, SOX2 is capable of modulating a significant portion
of the hESC-like module. Altogether, these findings strongly argue
for a direct contribution by SOX2 to these ESC-like molecular traits
in lung SCC in vivo. The next question that we considered was the
possible functional consequences over-expression of SOX2 on lung
squamous cell carcinomas.
Consequences of SOX2 Over-Expression on Lung SCC
Malignant Phenotype
To identify likely direct targets of SOX2 in lung SCC, we
analyzed the correlation/anti-correlation between SOX2 expres-
sion levels and the known SOX2 direct target genes in the tumors.
Among known SOX2-activated targets, 71 genes significantly
correlated with SOX2 expression and were over-expressed in lung
SCC (Figure 4 panel E, FDR ,10
22). Known SOX2-repressed
direct targets were relatively enriched as well, but as expected, they
were among genes anti-correlated to SOX2 expression in the
tumors (Figure 4 panel E, FDR =0.13). Together, they form a list
of 97 known SOX2 target genes directly deregulated downstream
Figure 3. SOX2 immunohistochemical analysis in 51 advanced lung SCCs. A. Sox2 staining pattern in a normal human lung sample (left
panel: bronchioli; and right panel: alveoli). SOX2 is detected at a low level in the cytoplasm of all bronchial and bronchiolar epithelial cells, and
staining intensity is strong in the nucleus of 30% of these cells. Alveolar epithelial cells are negative. B. Sox2 staining in the five tumors with high-level
3q26.33 amplifications. SOX2 is strongly expressed in the nucleus of most tumor cells (.80%). C. Summary of staining scores for the 51 lung SCCs.
Staining was scored according to intracellular localization (cytoplasmic or nuclear) and intensity. For each category, the number of cases is indicated,
and the corresponding percentage (over the series of 51 samples) is indicated between brackets. SOX2 activation, as defined by stronger nuclear
staining and detection in a higher proportion of cells when compared to normal lung epithelial cells, is observed in a wide majority of lung SCCs
(67%). All pictures of tumors were acquired at 250x magnification.
doi:10.1371/journal.pone.0008960.g003
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is significantly enriched in cell cycle genes, a meta-signature of
poor differentiation in cancer and embryonic and neural SC-
specific gene modules (not shown). The over-represented cell cycle
genes include several crucial regulators of cell cycle progression,
such as CDC2, CDK1, and E2F3 (Figure 5 panel C), suggesting that
SOX2 over-expression contributes to perturbation of the cell cycle
in primary lung SCC. To take into account indirect gene
deregulations downstream of SOX2, we computed all overlaps
between the SOX2-squamous in vitro model and the two lung SCC
signatures (present in SOX2-squamous and in any of the lung
SCC signatures). This process resulted in a consolidated list of 142
genes (Table S4). The ECM-receptor interaction pathway was
significantly enriched among up-regulated genes, comprising
collagens 1A1 and 3A1 and Integrins b1 and b8. Known TSGs
(Tumor Suppressor Gene) and apoptosis inducers (Trail, Caspases
1 and 4) were found to be down-regulated and several
transcription factors, secreted signaling molecules and a RAS-like
oncogene (Rit1) were up-regulated. All of these genes stand as
sound candidates as they are downstream of SOX2 and have the
potential to impact lung SCC carcinogenesis. Among them (genes
from Table S4), we selected 16 outstanding candidate genes
selected for their strong relevance to cancer biology, as indicated
by the scientific literature (Table 1).
To perform functional analyses of the consequences of SOX2
over-expression, we established three human lung epithelial cell lines
stably over-expressing SOX2 (Figure S4). Noting several cell cycle
genes in the above-mentioned gene lists, we initially checked the
proliferation rate of these cell lines in vitro, but uncovered no
differences(data not shown).Wethereforetested their migratoryand
invasive capacities. While no significant difference was observed for
cell invasion (data not shown), SOX2 over-expression significantly
increased the migratory activity of the three cell lines as assessed
using a wound healing in vitro assay (Figure 6). We next investigated
the effects of SOX2 over-expression on anchorage-independent
growth of BEAS-2B cells using the soft-agar colony formation assay.
Figure 4. A global SOX2 imprint on the lung SCC transcriptome towards an embryonic stem cell-like molecular phenotype. A.
Selected molecular signatures enriched in the lung SCC signatures 21 and 22. For each signature, enrichments were queried using the molecular
signatures database. Highly significant enrichment of both embryonic and neural stem cell-specific molecular signatures was observed in the lung
SCC transcriptome (all with p,10
231, hypergeometric distributions). B. Enrichments of ESC-like gene modules with known relevance for epithelial
cancers in lung SCCs. The GSEA tool was used to query enrichments of the human ESC-like (left panel) and the human ESC consensus (right panels)
gene modules in the lung SCC dataset-1. Significant enrichments are observed in lung SCCs (both FDR ,0.02). C. Venn diagrams of the overlaps
between the 345 SOX2 target genes in hESCs and the lung SCC signatures 21 (left graph) or 22 (right panel). Gene numbers are indicated within the
corresponding sections, and the p-value is below each graph (hypergeometric distribution). D. Enrichments of known SOX2 target genes in lung
SCCs (dataset-1). The GSEA tool was used to query enrichments of SOX2 target genes that are activated (left panel) or repressed by SOX2 (right panel)
in human ESCs. Significant enrichment of SOX2-activated target genes is observed among genes over-expressed in lung SCCs (FDR ,0.03) and of
SOX2- repressed genes among genes under-expressed in lung SCCs (FDR =0.13). E. Enrichments of ESC-like gene modules with known relevance for
epithelial cancers among genes correlated to SOX2 expression in lung SCCs. The GSEA tool was used to query enrichments of the human ESC-like and
the human ESC consensus gene modules in the lung SCC dataset-1 using SOX2 expression to define phenotypes. Significant enrichments are
observed (both FDR ,0.05).
doi:10.1371/journal.pone.0008960.g004
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PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8960Figure 5. List of known direct SOX2 targets in hESCs that significantly correlate and anti-correlate to with SOX2 expression in lung
SCCs. A. The 71 genes that are known SOX2-activated target genes in human ESCs and significantly correlate with SOX2 expression in lung SCCs. B.
The 26 genes that are known SOX2-repressed target genes in human ESCs and significantly anti-correlate with SOX2 expression in lung SCCs. Panels
A and B: For each gene in each sample, expression is represented by a square with a color that codes for the level as a gradient (dark blue, low
expression, to dark red, strong expression). C. Genmapp view of the enriched cell cycle regulators that are targets of SOX2 in hESCs and correlate
with SOX2 expression in lung SCCs. Green boxes represent the genes that are significantly enriched among the known SOX2-activated target genes
in human ESCs and correlate to SOX2 expression in lung SCCs.
doi:10.1371/journal.pone.0008960.g005
SOX2 Is an Oncogene in LSCC
PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8960While BEAS-2B control cells gave rise to some small colonies, as
previously reported [31], SOX2 over-expression induced a signif-
icant increase in the number of colonies that were much larger and
became macroscopically visible (Figure S5), which is a hallmark of
malignant cells [32]. These results indicate that SOX2 over-
expression significantly stimulates BEAS-2B cell anchorage-inde-
pendent growth and suggests that SOX2 could represent a
transforming oncogene when over-expressed in lung epithelial cells.
Table 1. Selection of 16 cancer-related genes as potential mediators of the malignant phenotype of lung SCCs downstream of
SOX2.
Gene Symbol Gene title Comment
CBX5 chromobox homolog 5 (HP1 alpha homolog,
Drosophila)
Cooperates with Myb and Hmgb3 to form ESC-like myeloid Leukemic Stem Cells.
GATA3 GATA binding protein 3 Transcription factor, poor prognosis marker in endometrial and breast cancers.
MYCL1 v-myc myelocytomatosis viral oncogene
homolog 1, lung carcinoma derived (avian)
L-Myc oncogene.
HOXB7 homeobox B7 In breast cancer, promotes EMT, the angiogenic switch, tumor progression and lung
metastasis.
HOXC4 /// HOXC6 homeobox C4 /// homeobox C6 Over-expressed in primary prostate tumors and lymph node metastases
RIT1 Ras-like without CAAX 1 Ras-like transforming oncogene.
IGFBP5 insulin-like growth factor binding protein 5 Pro-fibrotic factor in lung, induces EMT. Prognostic value in breast cancer.
NRG1 neuregulin 1 EGFR/ERBBs ligand, induces lung branching morphogenesis through PI3K pathway
and lung epithelial cells proliferation.
FGFBP1 fibroblast growth factor binding protein 1 Mobilizes and activates stored FGFs to induce the angiogenic switch in tumors.
FHL1 four and a half LIM domains 1 Tumor suppressor gene
PTGIS prostaglandin I2 (prostacyclin) synthase Over-expression prevents lung carcinogenesis in mice model. Anti-inflammatory
and anti-proliferative roles.
CASP1 caspase 1, apoptosis-related cysteine peptidase
(interleukin 1, beta, convertase)
Apoptosis inducer
CASP4 caspase 4, apoptosis-related cysteine peptidase Apoptosis inducer
CLU clusterin Absence of Clusterin in NSCLC is associated to a shorter survival
TGFBR3 transforming growth factor, beta receptor III Suppresses NSCLC cells invasion and tumorigenicity.
TNFSF10 tumor necrosis factor (ligand) superfamily,
member 10
TRAIL, Apoptosis inducer
Deregulated genes in lung SCC signatures and the SOX2-squamous signature (from Table S4) were selected based on their known function related to cancero r
correlation to patient prognosis in the scientific literature.
doi:10.1371/journal.pone.0008960.t001
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Figure 6. Consequences of Sox2 over-expression in the wound healing in vitro assay. A. Pictures were acquired at the beginning of the
experiment (t=0, immediately after wounding) and from the same field at the end of the experiment (t=24 h for this example from the Calu-1 cell
line). B. Quantification of wound closure for the three cell lines (BEAS-2B, NCI-H226 and Calu-1). Wound sizes were measured at the beginning and
end of the experiment to calculate the percentage of wound closure for control and SOX2 over-expressing cells for each of the three cell lines. SOX2
over-expression significantly stimulates cell migration compared to control cells (student’s t-test).
doi:10.1371/journal.pone.0008960.g006
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effect of Sox2 over-expression on tumor formation and growth in
immunocompromised mice injected subcutaneously. The highly
tumorigenic NCI-H226 cells lead to systematic tumor growth with
no change in growth rate according to SOX2 status (Figure 7
panel A). By contrast, BEAS-2B-SOX2 cells gave rise to tumors in
all four injected animals, in contrast to control cells (Figure 7 panel
A–D). The BEAS-2B-SOX2-derived tumors grew relatively
slowly: volumes reached 0.25–1 cm
3 within 3 to 6 months. This
finding strongly suggests that additional hits downstream of SOX2
over-expression might be required to allow for full transformation
of BEAS-2B cells and tumor expansion in vivo. At the histological
level (Figure 7 panel B), the tumors were mainly composed of
poorly differentiated SCC of the basaloid subtype [33]. Remark-
ably, within the same tumor, restricted areas (about 20% of the
tumor section surface) displayed well- or moderately-differentiated
features with individual cell keratinization (Figure 7 panel C),
which is commonly seen in human basaloid variants of SCC [34].
Interestingly, local invasion of tumor cells into the dermis was also
noted in one case (Figure 7 panel D). At the molecular level, low
levels of apoptosis were noted (as assessed by cleaved caspase-3
staining; data not shown). The tumor cells homogeneously
expressed nuclear SOX2, and most of them were cycling, as
assessed by Ki67 staining. Further, keratins 5/6, which are
squamous differentiation markers, were heterogeneously expressed
(Figure 7 panel E). In conclusion, Sox2 over-expression is capable
of converting non-tumorigenic human lung bronchial epithelial
cells to a tumorigenic state, enabling them to grow as poorly
differentiated squamous tumors in immunocompromised mice.
Finally, we assessed the consequences of SOX2 knockdown
in lung squamous cell lines using two independent shRNAs that
very efficiently knockdown SOX2 protein expression (Figure 8
panel A). Upon lentiviral-mediated transduction of the three lung
squamous cell lines with these two SOX2-targeting shRNAs, we
Figure 7. Consequences of Sox2 over-expression in vivo.A .Tumor incidence upon subcutaneous implantation of human lung squamous
control- and SOX2-transduced cell lines in nude mice. For each cell line, the number of tumors that developed is represented with respect to the
number of injections for each cell type (control or SOX2-transduced, n=4 injected animals each). Tumor incidence is unchanged for the NCI-H226
highly tumorigenic cell line, whereas BEAS-2B cells become tumorigenic upon Sox2 over-expression. B. Hematoxylin and Eosin (H&E) staining of a
representative area of a BEAS-2B-Sox2 subcutaneous tumor (magnification=1006). A majority of the tumor area (around 80%) has typical traits of
poorly differentiated basaloid variants of squamous cell carcinoma. C. H&E staining of representative areas of the same BEAS-2B-Sox2 subcutaneous
tumor as in panel B (magnification=1006). Around 20% of the tumor area has typical traits of poorly to moderately differentiated squamous cell
carcinoma, with individual cell keratinization. D. H&E staining of one BEAS-2B-Sox2 subcutaneous tumor (magnification=506). In this case, local
tumor cell invasion into the dermis was observed (arrowheads). E. Immunohistochemistry for SOX2, Keratins 5/6 and Ki67 (left, middle and right
panels, respectively; magnifications=2006). Tumors homogeneously express SOX2 and Ki67 and heterogeneously express Keratins 5/6, which are
squamous cell differentiation markers.
doi:10.1371/journal.pone.0008960.g007
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line), whereas control-transduced cells re-grew normally. Three
independent experiments (with the two SOX2 targeting shRNAs
and the three cell lines, BEAS-2B, NCI-H226 and Calu-1) failed to
establish stably transduced cells, showing that SOX2 expression is
critical for the survival of these cell lines. Consequently, we
explored the cell death mechanism at an early time point after
positive selection of transduced cells by FACS analysis using
Annexin V and Propidium Iodide (PI) staining. An increase of
early apoptotic (AnnexinV+/PI-) and late apoptotic/necrotic
(AnnexinV+/PI+) cell populations were observed in the SOX2
knockdown cells, as was shown for the BEAS-2B cells (Figure 8
panel B). Altogether, these results unambiguously demonstrate
that SOX2 expression is essential to lung squamous cell line
survival.
Discussion
Using array-CGH, we characterized chromosome 3 aberrations
in a series of 26 lung SCCs. The short arm of chromosome 3
displays several discontinuous sites of recurrent losses resulting in
combined allelic losses, which may affect different TSGs involved
in lung tumorigenesis [35]. The OGG1 and RAD18 loci were
the most frequently lost (60% of cases) in our study, and these
genes are good TSG candidates given their DNA repair-related
functions. On the long arm, the whole 3q26-qter region commonly
(around 60%) experiences low-level gains. Therein, the PIK3CA
and RFC4 loci are gained in a wide majority ($80%) of advanced
lung SCCs, as previously reported [5,6]. PIK3CA is a well-
established oncogene [36] and RFC4 is recurrently over-expressed
in a broad range of solid tumor types [26].
High-level gene amplifications have been reported for several
3q26-qter region loci [6,7]. Incidentally, we found sporadic
amplifications of the EIF4G1 and EIF5A2 loci (one to two tumors
each). More consistently, we uncovered high-level amplifications
of the SOX2 region (2 Mb around this gene) as the most frequent
chromosome 3 amplification site in three independent cohorts
(.130 lung SCCs in total), with about 20% of tumors carrying
3q26.33 amplifications. This site is also among the most frequently
amplified in the whole genome of lung SCCs. This finding is in
line with the amplification rate of canonical oncogenes, such as
EGFR, ERBB2, C-MYC, N-MYC, CCND1, MDM2, and RAS, which
generally range from 10 to 30% in different tumor types [2].
Therefore, the high occurrence of 3q26.33 amplifications in lung
SCCs likely reflects a critical cellular selective advantage conferred
by the activated oncogene(s) in this region. In addition, the very
high frequency of copy number increases of the locus (60 to 80%
of tumors with gains) strongly suggests that these aberrations may
be constitutive or at least a very common theme of lung SCC
carcinogenesis and possibly also cervical cancer.
Gene amplification is a known mechanism for oncogene activa-
tion and is implicated in tumor progression by the step-wise
selection of tumor cells with increasing malignant capabilities [2,3].
Within an amplicon, the expression of several genes is usually
affected by gene dosage. By-stander genes can be up-regulated due
to their position, but do not necessarily bring any functional
advantage to the tumor cells. By contrast, driver genes are over-
expressed as a result of copy number increases and functionally
participate in the malignant phenotype. In this report, most of the
nine genes mapping in the 3q26.33 core amplicon were found to be
over-expressed due to copy number increases, with the exception of
LAMP3. Among them, SOX2, DCUN1D1, FXR1 and ATP11B are
also over-expressed in lung SCC when compared to normal lung in
published studies in which genomic copy numbers were unknown.
These genes may be commonly involved in lung carcinogenesis and
knowledge of their normal function may indicate their relevance to
carcinogenesis. In that respect, the oncogenic potential DCUN1D1
was proposed to act through the Gli1/Hedgehog signaling pathway
[8], which is active in less than 10% of lung SCCs [37]. Sarkaria et
al. demonstrated that DCUN1D1 over-expression transforms NIH-
3T3fibroblastsandrenders themtumorigenicin vivo.More recently,
this group showed that DCUN1D1 participates in cullin neddyla-
tion [38] and induces NIH-3T3 fibroblast invasion in vitro by
activating MMP-2 expression [39]. Its yeast and nematode
homologues play a role in mitotic spindle regulation [40] and act
asscaffoldingE3ubiquitinligasescriticalforcullinneddylation[41].
DCUN1D1 over-expression could thus have pleiotropic effects and
may be a sound candidate driver oncogene of 3q26.3 amplifications
in lung SCCs.
Here, we describe high SOX2 over-expression as a direct
consequence of 3q26.33 copy number increases and found that
Figure 8. Consequences of shRNA-mediated knockdown of SOX2. A. Western blot analysis of cells transfected with SOX2-specific shRNA-
expressing plasmids. Two shRNAs were found to very efficiently knockdown SOX2 protein expression in 293T cells over-expressing SOX2 (see
Materials and Methods). B. FACS analysis of AnnexinV and Propidium Iodide stained BEAS-2B cells. Control and SOX2 shRNA-transduced cells were
stained to determine the proportions of cell death by FACS analysis. Proportions of early apoptotic (AnnexinV+/PI-) and late apoptotic/necrotic
(AnnexinV+/PI+) cells are strikingly increased in SOX2 knockdown cells.
doi:10.1371/journal.pone.0008960.g008
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Accordingly, we demonstrated that over-expression of SOX2 in
lung epithelial cells promoted cell migration and anchorage-
independent growth in vitro. We showed that SOX2 over-expression
can be transforming and lead to the growth of poorly differentiated
basaloid variants of squamous tumors in immunocompromised
mice [33,34]. In addition, SOX2 expression was found to be critical
for survival of lung cell lines, as indicated by SOX2 silencing RNA
interference experiments. These findings unambiguously indicate
the oncogenic properties of SOX2 and designate it as a driver gene.
Our results, together with previous characterizations of DCUN1D1
function, suggest that 3q26.3 may be a new example of a multi-
oncogenic locus [9]. DCUN1D1 and SOX2 may be co-driver genes
of 3q26.3 amplification that synergistically modulate different
molecular traits and result in a more aggressive tumor phenotype.
Further investigations are required to elucidate their cooperation
and respective involvement in carcinogenesis. Such experiments
should involve concomitant functional analyses of the modulated
phenotypical traits in vivo. We propose a model where SOX2 over-
expression confers higher tumorigenicity and contributes to loss of
differentiation by lung squamous epithelial cells and where
DCUN1D1 increases invasive capabilities through MMP2 [39]
along with other effects [38,40,41].
We demonstrate striking and systematic up-regulation of SOX2
and SOX2OT among tumors with either 3q26.3 amplifications or
gains. Concomitant over-expression of both genes suggests that
they may be co-regulated. SOX2 is contained in an intron with the
SOX2 Overlapping Transcript encoding gene. Both genes are
transcribed in the same orientation. SOX2OT is thus not an
antisense RNA, but a large non-coding RNA with an elusive role.
Deciphering its function remains of interest, especially in light of
the growing body of evidence for the importance of non-coding
RNAs in physiopathological situations, such as cancer [42]. SOX2
is a functionally well-characterized transcription factor and an
outstanding oncogene candidate. Our finding of frequent and
intense SOX2 nuclear staining in lung SCC is consistent with its
role in gene expression regulation.
In normal fetal chick and murine lungs, Sox2 is expressed in the
primary bronchus epithelium, but not in distal bronchiolar buds
[16,43,44]. In the adult murine lung, Sox2 is expressed by ciliated
epithelial cells and induced in bronchiolar epithelial ciliated,
squamous and cuboidal cells upon injury [45]. Over-expression of
Sox2 in transgenic mouse lung epithelium leads to an increase in
committed precursor-like cells, notably basal cells, and reveals its
role in branching morphogenesis as well as in the control of lung
epithelial cell differentiation [16]. Apparently contradictory with
our results, it has also been reported that SOX2 over-expressing
lungs are reduced in size, which may result from a slight but not
statistically significant reduction in proliferation [16]. However,
given the cellular diversity of the lung tract (and localization
differences of these cell types between mouse and human) and the
absence of definite identification of the cell of origin of lung SCC,
extrapolation of SOX2 cellular consequences in the context of
lung cancer from mouse normal lung development data is difficult.
Here we show that Sox2 is expressed in normal human lungs in
an overall similar pattern to that for the mouse. It will be of further
interest to determine the extent to which Sox2 participates in
human lung epithelial stem and progenitor cell homeostases, as in
the mouse [16,45].
In tumors, SOX2 is up-regulated in early pancreatic cancer
lesions [46], where it is nuclear in basal cells or in the vicinity of
necrotic areas and is activated in a majority of advanced tumors
[47]. SOX2 is associated with an immature phenotype in CNS
teratomas and glioblastomas [48]. In breast cancer, it has been
proposed that 3q gains activate SOX2, thereby driving a basal cell-
like phenotype [49]. In the MCF-7 breast cancer cell line, SOX2
over-expression stimulates anchorage-independent growth and
tumor growth, while its knockdown produces converse effects [50].
These data are in accordance with our results obtained in lung
squamous cell lines. Chen et al, [50] also report that the SOX2-
positive action on breast cancer cell proliferation and tumorigen-
esis is mediated by synergistic activation of CCND1 expression with
b-catenin. Finally, SOX2-activated target genes (that have been
defined as such in hESCs) are up-regulated in basal-like breast
tumors and in poorly differentiated grade 3 breast tumors [27].
In lung SCC, we have shown here that SOX2 over-expression
may contribute to direct cell cycle regulation and proliferation by
affecting key regulators of the cell cycle, with exclusion of CCND1.
Key transcription factors controlling wide transcriptional programs,
such as SOX2, rely on regulatory networks to ensure tissue- and
time-specificmodulationoftheirtranscriptionalprograms[51].The
global readoutis highly dependent on the availability of the partners
in a given cell type, especially for SOX proteins [52]. Such cell type
specificity in cofactors may account for some of the differences
observed downstream of SOX2 activation in breast cancer and lung
SCC. The 16 cancer-relevant gene list that we generated, which
includes genes that are likely targets of SOX2 and altered in lung
SCC, is a good starting point to evaluate the molecular mechanisms
downstream of SOX2. We have shown that SOX2 over-expression
is capable of transforming non-tumorigenic lung squamous BEAS-
2B cells, enabling them to form slowly growing tumors in vivo.A
possible explanation for this relatively mild transforming power is
that additional hits are required downstream or in cooperation with
SOX2 activation and that a specific genetic makeup is required in
thetumor to fully allowfor SOX2 oncogenicaction.It will therefore
be of further interest to determine which alterations are capable of
cooperating with SOX2 activation in lung SCC. In addition, our
results reveal activation of embryonic and neural SC molecular
phenotypesinlungSCCandsupportamajorcontributionofSOX2
thereto in vivo. Finally, the hESC consensus and hESC-like gene
modules, which areactivated in poorly-differentiated and aggressive
epithelial cancers [27,28], are commonly activated in lung SCCs as
well. SOX2 may be directly involved in this process, as we have
shown. These results led us to speculate that SOX2 induces a poorly
differentiated state that may favor cellular plasticity and help cells to
cope with the changing environment during tumor progression.
Interestingly, Sox2 is expressed by cancer stem cells (CSCs, Cancer
Stem Cells, cancer cells with tumor-initiating properties) derived
from pediatric brain cancers [53], and SOX2 knockdown arrests
proliferation and results in a loss of tumorigenicity of glioblastoma
CSCs [54]. Such CSCs have since been identified in various solid
tumors, including squamous tumors [55–57]. Given the role of
SOX2 in the control of normal embryonic and neural SCs
homeostases and our identification of SOX2 as a novel oncogene
in lung SCC, it will be of interest to dissect its involvement in cancer
stem cells (CSCs) isolated from squamous tumors.
Our study shows that Sox2 is an oncogene in lung SCC and a
strong candidate for driving the recurrent 3q26.33 amplifications in
these tumors. Sox2 provides a major contribution to transcriptome
deregulation and is thus very likely to exert pleiotropic effects on lung
SCC carcinogenesis. During the manuscript submission process, a
report on the role of SOX2 as an oncogene in lung SCC was
published [58], providing corroborative evidence for our conclusions.
Further in vivo studies will be critical to comprehensively dissect
SOX2-specific effects. We speculate that SOX2 might be involved in
several steps during lung SCC progression. First, SOX2 is capable of
transforming and conferring tumor-initiating properties to human
lung squamous cells, as we demonstrated. Second, SOX2 contributes
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in advanced lung SCC, as is also suggested for SOX2 in basal-like
breast cancer [27,49] and other tumor types [48]. Further
investigations are required to assess whether Sox2 plays a role in
the homeostases of normal bronchiolar epithelial stem cells and of
lung squamous cancer stem cells. This work requires isolation of the
normal lung and cancer stem cells and the identification of the cells-
of-originoflung SCC. Altogether,SOX2 could participateintumor
progression at several steps during carcinogenesis by promoting
both tumor cell de-differentiation and maintenance of a stem/
progenitor cell-like phenotype.
Materials and Methods
Ethics Statements
Human tumor samples came from a Grenoble biobank
approved by the French Research Ministerium with patient
informed consent (written approval Nu AC-2007-23). Data were
analyzed anonymously. Mouse experiments were performed in
accordance with Swiss guidelines and approved by the Veterinar-
ian Office of Vaud, Switzerland.
Samples, Cell Lines and Transductions
Patients were untreated prior to tumor excision. DNA was
extracted using the phenol/chloroform method, and RNA was
extracted using Trizol (Invitrogen). BEAS-2B (an immortalized but
non-tumorigenic cell line in nude mice, CRL-9609), NCI-H226
(CRL-5826), and Calu-1 (HTB-54) cell lines originally established
from SSC tumors (and tumorigenic in nude mice) were obtained
from ATCC (http://www.atcc.org/). BEAS-2B was grown in
RPMI 1640 without Hepes (Gibco) and 10% fetal calf serum and
gentamicine. NCI-H226 was grown in RPMI 1640 without Hepes
(Gibco), 10 mM Hepes, 2.5 g/L glucose, 1 mM Sodium Pyruvate,
10% fetal calf serum and gentamicine. Calu-1 was grown in MEM
alpha medium (Gibco), 10% fetal calf serum and gentamicine.
These cell lines were transduced using pRRL third-generation
lentiviral vectors [59] for GFP and luciferase (control) or GFP and
Sox2 expression. Transduced cells were sorted by FACS (based on
GFP expression) and re-cultured for expansion.
Array-Comparative Genomic Hybridization
Two high-resolution chromosome 3 arrays, prepared as previ-
ously described [60], were used. The ‘‘chromosome 3’’ array served
to analyze the initial 26 tumor series. The ‘‘contig’’ array (an
updated version that provides a tiling coverage of the 3q26.33 locus)
was used to reanalyze tumor DNAs with 3q26.3 amplifications
found in the first screen. Data are available in GEO (GSE15080).
IntegraChip
TM BAC pangenomic arrays (IntegraGen) were also
used to analyze two tumors (#15 and 35). Publicly available array-
CGH data were downloaded from GEO. Details on data sources
and other supplementary methods are given in Text S1.
RT-PCR and Immunohistochemistry
RT-qPCR and immunohistochemistry were performed as
described [61–63].
Genome-Wide Gene Expression and Bioinformatic
Analyses
We analyzed transcriptome data by comparing lung SCC and
normal lung tissue data [20,21]. BEAS-2B (Sox2 vs. control) cells
were profiled following standard protocols (HG U133+2.0 arrays,
IGBMC Affymetrix core facility). Details are given in Text S1 and
Genelist S1.
shRNAs
A control scramble shRNA and two different shRNAs
targeting SOX2 in pLKO.1-puro were used (OpenBiosystems;
shRNA#1, clone ID TRCN0000085750; shRNA#2, clone ID
TRCN0000085749). SOX2-targeting shRNAs were validated
upon transient co-transfections of a SOX2 (and GFP) expression
construct and either a control shRNA or a SOX2-targeting
shRNA in 293T cells. Upon lentiviral-mediated transductions of
lung squamous cells using these constructs, transduced cells were
selected by adding 1 mg/ml puromycin (Sigma) to the media at
48 h post-transduction.
FACS Analysis of Annexin V and PI Stained Cells
Control- and SOX2-shRNA-transduced cells were stained using
AnnexinV-FITC (BD Biosciences) and Propidium Iodide (Sigma)
5 days after puromycin selection and were analyzed on a FACS
Calibur.
Tumor Growth In Vivo
In vivo tumor growth assays followed institutional and national
regulations. Female NMRI nude mice (6–8 weeks old, Elevage
Janvier, France) were submitted to subcutaneous injections of
2.5610
6 cells in 100 ml PBS. Each animal received both control-
(left flank) and Sox2-transduced (right flank) cells. In one
experiment, four animals were tested with each cell line (BEAS-
2B and NCI-H226).
Accession Numbers
The MIAME-compliant microarray data are available in GEO
(SuperSeries record GSE15080).
Supporting Information
Text S1 Additional Materials and Methods information.
Found at: doi:10.1371/journal.pone.0008960.s001 (0.09 MB
PDF)
Figure S1 Array-CGH analyses of lung and uterine cervix
SCCs. A. Whole genome array-CGH profiles for lung tumors #15
(left panel) and 35 (right panel). For both tumors, the 3q26.33
amplification (green arrow) represents the highest copy number
increase detected over the entire genome. Chromosome numbers
are indicated above the graph, and the different chromosomes are
separated by the vertical lines. B. Amplification frequencies of
chromosome 3 loci in two independent cohorts of uterine cervix
SCCs. In the two cohorts, the maxima of amplification are
observed for the 3q26.33 locus (green arrow). C. Individual
Chromosome 3 array-CGH profiles obtained for lung tumors #15
and 35 reanalyzed with the 3q26.3 tiling array. The green dashed
rectangles indicate the regions presented in panel D. D. Individual
array-CGH profiles for tumors #15 and 35 with the 3q26.3
tiling array: insets of the chromosome 3 interval from 170 to
190 Mb.
Found at: doi:10.1371/journal.pone.0008960.s002 (1.03 MB TIF)
Figure S2 GSEA-based enrichment analyses of lung SCC
dataset-2. A. Enrichments of human ESC-like molecular pheno-
types among the genes deregulated in lung SCC dataset-2. The
human ESC consensus gene module (FDR ,10-2; left panel) and
the human ESC-like gene module (FDR ,10-2, right panel) are
significantly enriched among the genes over-expressed in lung
SCCs. B. Enrichments of SOX2 targets in human ESCs among the
genes deregulated in lung SCC dataset-2. Genes that are known,
direct SOX2-activated targets in human ESCs are significantly
enriched among genes over-expressed in lung SCCs (FDR ,0.02,
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PLoS ONE | www.plosone.org 13 January 2010 | Volume 5 | Issue 1 | e8960left panel). Genes that are known SOX2-repressed targets in
human ESCs are significantly enriched among genes down-
regulated in lung SCCs (FDR ,0.05, right panel).
Found at: doi:10.1371/journal.pone.0008960.s003 (1.01 MB TIF)
Figure S3 Characterization of the SOX2-squamous signature. A.
Venn diagram representing the overlap between the SOX2
squamous signature and the SOX2 targets in human ESCs. Gene
numbers are indicated in the corresponding section. The p-value
indicates the significance of overlap (hypergeometric distribution).
B. Significantly Enriched Gene Ontology Biological processes in
the SOX2-squamous signature. C. Significantly Enriched Gene
Ontology Cellular compartments in the SOX2-squamous signa-
ture. Panels B and C: All represented categories are significantly
enriched (FDR,10-2 and p,10-5). D. Enrichments of the human
ESC-like gene module upon SOX2 over-expression in BEAS-2B
cells. A significant portion (292 genes, 23%) of the human ESC-
like gene module is activated upon SOX2 over-expression in
BEAS-2B cells (FDR =0.12).
Found at: doi:10.1371/journal.pone.0008960.s004 (0.67 MB TIF)
Figure S4 Western blot analysis of SOX2 expression in
transduced lung squamous cell lines. BEAS-2B, NCI-H226, and
Calu-1 cells were transduced with a SOX2 lentiviral vector (or
control). For each cell line, protein extracts were submitted to
western blot analysis after normalization of protein loading.
Endogenous SOX2 is visible as a thin band in the three cell lines
with increased expression in NCI-H226, which contains a gain of
this genomic regions by array-CGH. This form probably
corresponds to a posttranslational modified protein, such as that
described previously [66]. A similar pattern of migration was
observed in SOX2 over-expressing cells; see figure 2B in [67].
Phosphorylation and sumoylation have also been reported for
SOX2. On the contrary, cell lines transduced with a SOX2 plasmid
produced a large amount of unmodified SOX2.
Found at: doi:10.1371/journal.pone.0008960.s005 (0.06 MB
PDF)
Figure S5 Effects of SOX2 over-expression in BEAS-2B cells on
anchorage-independent growth. A. Colony number quantification.
SOX2 over-expression leads to a significant increase in BEAS-2B
colony number. Of note, these colonies become are largely visible
macroscopically upon SOX2 over-expression. B. Colony size quan-
tification. SOX2 over-expression leads to a significant increase in
colony size. Representative images of colonies from BEAS-2B
control and SOX2 cell lines are presented.
Found at: doi:10.1371/journal.pone.0008960.s006 (3.30 MB TIF)
Table S1 The 50 most over-expressed genes in lung SCC versus
normal comparison (dataset 1). Gene Symbol, Gene description,
Ratio (log2 value) lung SCC/normal.
Found at: doi:10.1371/journal.pone.0008960.s007 (0.04 MB
XLS)
Table S2 SOX2 immunostainings individual results for 51 lung
SCC. Individual nuclear and cytoplasmic staining scores obtained
for the 51 primary tumors. The 5 tumours found with high level
amplifications in the initial arrayCGH screen of 26 tumours are
indicated in bold.
Found at: doi:10.1371/journal.pone.0008960.s008 (0.04 MB
XLS)
Table S3 Known SOX2 target genes significantly correlated to
SOX2 expression in human lung SCC. Union of the 71 SOX2
activated target genes significantly correlated to SOX2 expression
and the 26 SOX2 repressed genes significantly anti-correlated to its
expression in lung SCC (97 genes in total).
Found at: doi:10.1371/journal.pone.0008960.s009 (0.04 MB
XLS)
Table S4 Union of the SOX2-squamous and the lung SCC
signatures. Union of the SOX2-squamous and either of the lung
SCC signatures (142 genes in total). Expression ratios (log2 values)
are indicated.
Found at: doi:10.1371/journal.pone.0008960.s010 (0.04 MB
XLS)
Genelist S1 Supplementary genelists xls file, several sheets.
Found at: doi:10.1371/journal.pone.0008960.s011 (0.42 MB
XLS)
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